In 1402 patients allografted in Europe during the period 1990-2000 with an HLA-identical sibling in first remission (CR1), the median interval from CR1 to allotransplant (96 days) was a major prognostic factor, patients transplanted earlier having a worse outcome. We studied in depth the 414 fully evaluable patients transplanted less than 96 days after achieving CR1; in these patients, only three factors predicted for the outcome by multivariate analysis: patient age, CR1 achievement with one or more induction courses and the recipient/donor sex combination. These three factors overcame the information from cytogenetics and source of stem cells. Three prognostic groups could be identified in relation to the outcome, using a prognostic score affecting 1 to each poor risk factor (total from 0 to 3): Group 1 (good prognosis) includes patients o35 years old, achieving CR1 with one induction course and to be transplanted with any other sex combination than female to male (score 0); group 2 (intermediate) with one adverse factor (score 1); and group 3 (bad prognosis) with two or three adverse criteria (scores 2 and 3). In these three groups, the 3-year leukaemia-free survival was 5675%, 4874% and 2974% and the overall survival was 6575, 5374 and 2975%, respectively. Therefore, adult patients with ALL and a score of 0 or 1 are good candidates for an early transplant if they have an identical sibling donor. Patient age, response to induction and the sex of the HLA-identical family donor (if existing) are the strongest easy predictors of the outcome for an early transplant in an adult patient with ALL. No additional information is mandatory.
Introduction
Despite considerable improvement in the management of patients with haematological malignancies and steady improvement of outcome following haemopoietic stem cell transplantation, not more than 30% of all patients with acute lymphocytic leukaemia (ALL) are presently cured. In adult patients with ALL, transplanted with a geno-identical (family) donor, resistance of the disease to the conditioning regimen, transplant-related mortality (TRM) and the limited effect of graft vs leukaemia (as opposed to acute myelocytic and chronic myelocytic leukaemias (CML)) are believed to account for the high rate of overall failure which also includes a high rate of relapses, some of which occur late. 1 We reviewed the Acute Leukaemia Working Party (ALWP) EBMT registry for geno-identical transplants carried out for adult ALL in the 1990-2000 decade, and decided to focus on the relatively more homogeneous population of patients transplanted early, known to have a poorer prognosis than patients transplanted later. Indeed, the latter have a selection bias since, by definition, at the time of transplant they had not relapsed, therefore representing, already pretransplant, a population of patients with a better prognosis.
In patients transplanted early (defined as transplanted before the median interval from diagnosis to transplant observed in the total patient population), we wondered whether one might identify, from very simple clinical observation, the population(s) of patients that get maximum benefit from the transplant.
Materials and methods
From January 1990 to December 2000, 5141 adult patients transplanted for ALL were reported to the registry. A total of 3240 were allogeneic stem cell transplantations, and in 1871 the donors were geno-identical. Of these, 1402 patients were transplanted in first remission (CR1) with a myeloablative conditioning regimen. In these 1402 patients, the median interval from diagnosis to transplant (96 days) was a major prognostic factor, with a better outcome for patients transplanted late leukaemia-free survival (LFS: 5773% vs 4673%, P ¼ 0.003). We studied patients transplanted early with a poorer outcome.
Patients transplanted early (before day 96) Table 1 gives the characteristics for the 414 patients who were transplanted early, before day 96 (median duration of the interval). A total of 39% of the population had the Philadelphia chromosome and/or the bcr-abl translocation. An important difference with the whole population of patients was that 29% patients only reached CR1 with one induction course a much lower proportion for rapid remitters than in the whole population (79%), suggesting that absence of response to the first induction course was a possible motivation for the medical team to go for an early transplant; 31% of the patients were transplanted with the female donor to male recipient combination. The probability of acute graft versus host disease (aGVHD) and chronic GVHD (aGVHD) was 41 and 40%, respectively.
Statistical analyses
We first analysed the overall population and then Ph1+/bcr+ ALL patients. Since the interval from diagnosis to transplant was a major prognostic factor in the overall population (patients transplanted late had a higher LFS as they did not experience relapse before transplant), we decided to focus on the population of patients transplanted early.
The primary outcome was LFS defined as the time interval from transplant to first event (either relapse or death in complete remission). aGVHD was diagnosed and graded at each transplant centre according to Seattle criteria. 2 cGVHD was defined according to standard criteria. Patients surviving without relapse for more than 100 days post-transplant with sustained donor engraftment were considered as evaluable for chronic GVHD.
Values reported for quantitative variables were median and range. The following patient's characteristics or graft characteristics were analysed for their potential prognostic value on LFS: patient and donor characteristics (age, sex and sex matching), disease-related factors (WBC at the time of diagnosis, number of induction courses to reach CR1) and transplant-related factors (nucleated cell doses infused per kg, use of T depletion, conditioning regimen, interval diagnosis to transplantation). For continuous variables, the median was taken as a cutoff point.
Patients were censored at the time of relapse or at the last follow-up. Probability of LFS and GVHD were estimated by the product-limit method. 3 The significance of differences between curves was estimated by the log-rank test 4 (Mantel-Cox) . Then, all variables associated in univariate analyses with a P-value less than 0.10 were included in a Cox stepwise regression model. Based on prognostic scores derived from this proportional hazard model, each patient was classified into prognostic groups, after introducing significant interactions between all the remaining prognostic factors. All analyses were performed using the SPSS software.
Results
Of the 1402 patients with a geno-identical allotransplant carried out in CR1, 813 had all information available for a multivariate analysis of the prognostic factors on LFS. Four poor factors were found to decrease the LFS (Table 3) : patient age (435 years) (RR ¼ 0.53, 95% CI ¼ 1.24-1.89, P ¼ 0.0001), the combination of a female donor for a male recipient (RR ¼ 1.34, 95% CI ¼ 1.08-1.66, P ¼ 0.008), a long interval to reach CR1 (441 days, median value) (RR ¼ 1.3, 95% CI ¼ 1.05-1.59, P ¼ 0.014) and a short interval from CR1 to transplant, which might reflect a selection bias since patients transplanted late are those who did not relapse (RR ¼ 1.28, 95% CI ¼ 1.05-1.59, P ¼ 0.02); the 3-year LFS was 4673% for patients transplanted less than 96 days after CR1 vs 5773% for patients transplanted late (Figure 1) . Table 2 indicates prognostic factors for LFS, recognized by univariate analyses in the population of 414 patients transplanted early, that is less than 96 days post achievement of CR1. Cytogenetics were known in only 254 patients, of whom 98 (39%) had a Philadelphia chromosome and/or the bcr-abl translocation. The presence of the Philadelphia chromosome and /or the bcr-abl translocation in this population of patients transplanted early was associated with a lower LFS (3975 vs 4975%), but the difference was not statistically significant (P ¼ 0.15). As a result of the high proportion of missing data, we could not introduce this variable in the multivariate analysis. Only 7 patients were reported as having a t(4;11) translocation.
The multivariate analysis (348 patients with no missing value) identified three factors with a negative impact on LFS (Table 3) : age older than 35 years, achievement of CR1 with more than one course of chemotherapy induction and a female donor to male recipient combination. A poor risk group combining young patients but with the other two bad risk factors, or older patients with at least one other bad risk factor. Figure 2 indicates the LFS at 5 years in the three groups, 5675% in the 108 patients of the good risk group, 4874% in the 153 patients of the intermediate group and 2974% in the remaining 87 patients of the bad risk category.
When affecting a score of 1 for each poor risk factor when present (total from 0 to 3), the good risk group corresponded to a score of 0, the intermediate risk group to 1 and the poor risk group to scores 2 and 3.
Regardless of the interval from CR1 to transplant, the group of Ph1+/bcr+ ALL patients consisted of 166 patients. In these, the LFS at 3 years was 4574%. By univariate analyses, we identified the same three prognostic factors: younger patients (5476 vs 3176%, P ¼ 0.03), patients reaching CR1 with only one course of induction chemotherapy (5775% vs 2477%, P ¼ 0.002) and patients transplanted later postachievement of CR1 (5876 vs 3476%, P ¼ 0.005) did better. The negative impact of the female donor/male recipient combination was however not found in this population.
Regarding the distribution in the three risk groups defined above, 21, 29 and 33 patients with Ph1/bcr-abl+ were in the three risk groups, good, intermediate and poor, respectively. This corresponds, when evaluated on patients with an available chromosome and molecular biology assessment, to an incidence of 41, 37 and 62%, respectively. In each risk group category, there was no difference in LFS in relation to the presence or absence of the Ph1/bcr-abl translocation.
Discussion
This study was carried out on the EBMT registry with a very simple goal: define, for a rapid elaboration of the therapeutic scheme, easy and rapidly available criteria to identify in the clinics, among adult patients with an HLA-identical sibling, those that should proceed quickly to an HSC transplant and have their whole treatment programme hopefully completed by 4-5 months. To do this, we used the database from EBMT for the period 1990-2000; this database contained all clinical information used on a routine basis as well as important biological parameters to characterize ALL including FAB type and cytogenetics, at least in a majority of patients. However, reporting of immunophenotype was incomplete and it did not contain important information which became available only recently, such as the determination of minimal residual disease (MRD) following induction and each consolidation course; the amount of MRD by molecular biology has been shown to predict very accurately for the outcome, and has become a useful tool to tailor the therapeutic strategy. [5] [6] [7] [8] [9] [10] We were essentially interested in defining the prognostic factors in patients transplanted within 3 months of achieving CR1.
What this analysis shows is that young adults who are rapid remitters and have an HLA-identical sibling but no female donor for a male recipient have a probability of being disease free at 5 years of 5675%. Results can still be considered acceptable in the intermediate risk group consisting of younger patients yet with other bad risk factors or patients older but with no other bad risk factor. In contrast, patients in the bad risk group have a very low prospect for disease free survival with a 5-year LFS of only 2975%. The use of a prognostic score from 0 to 3 is just another easy way to apprehend the risk with 0 for the good risk group, 1 for the intermediate and 2 and 3 for the bad risk group.
The immunophenotype in ALL is an important recognized prognostic factor with a better outcome for T-ALL. In the EBMT database that we used, patients were classified only as having B-ALL or T-ALL, while full reporting of all immunophenotypes (pro-B, pre-B,B, pre-T,T, ect y) with specific CDs appeared only after January 1999. Nonetheless, on 267 patients with albeit limited immunophenotyping reported, indeed the LFS at 3 years was 4274% for B-ALL vs 6375% in T-ALL. Further, the distribution of B-and T-ALL differed in our three groups. It is 
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N-C Gorin et al therefore clear that a study similar to this should be carried out again in a few years, which would take into account the leukaemia phenotype. Since this information as well as the three factors identified by the present study are readily available, it is possible that immunophenotyping will appear as a fourth factor of interest in a model similar to the one we have proposed with three factors. Cytogenetics including the presence of the Philadelphia chromosome is universally recognized as the most important poor risk factor for outcome of ALL. 5, 11 The number of missing data was too high in our study and this did not permit us to include cytogenetics in multivariate analyses. However, the distribution of Ph1/bcr-abl+ ALL within the three risk groups was even. It is likely that the response to initial induction chemotherapy, an incontestable information, somehow reflects cytogenetics; it may also even be that, at least for the induction phase, the response to initial induction chemotherapy supervenes the information obtained by monitoring minimal residual disease. 8 In our study, a simple summation of the presence of the three risk factors identified did as well as the prognostic classification. As LFS is, in our view, the most important end point in adults with ALL and as TRM and relapse incidence are competing, our study was restricted to LFS. 12 Another similar study has been carried out previously within EBMT on patients transplanted for CML. 13 Five very simple previously recognized prognostic factors pretransplant as well as the disease phase were considered. With a score from 0 to 7, five groups of patients were individualized with LFS from 60 to 19%. The pretransplant factors considered included patient age, donor-recipient sex combination and interval pretransplant. In addition, the nature of the donor (related vs unrelated) and the stage of the disease (chronic, accelerated, acute phases) were introduced. As in our study, other factors known to influence outcome such as the viral status of the donors and recipients, the nature of the conditioning regimens and GVHD prevention were deliberately omitted.
The message from this study for adult ALL is somewhat similar to that obtained for CML; in fact, it is not a surprise that among patients transplanted early, those who are younger, are rapid remitters and are transplanted outside the female donor to male recipient combination have the best outcome. What this study shows is that clinical decision in the context of HSC transplantation can be taken with very simple information available very early in the course of the treatment of the disease. Therefore, treatment tailoring 14 does not necessarily rely on more complex biological tools. Of course, one cannot ignore that younger age and achievement of a rapid remission following induction likewise are also important favourable prognostic factors for other treatment strategies that use conventional chemotherapy with no HSC transplant and/or autologous haemopoietic stem cell transplantation. 9, [15] [16] [17] [18] [19] Also, although HSC transplantation in ALL can nowadays be considered somehow as relatively standardized over the world, there are still some variations in the transplant methodology that may have an impact on the outcome: as an example, the team from the City of Hope has recently reported a 3-year LFS as high as 81% in adult patients with Ph1+ ALL allotransplanted after 1992, and attributed this unusually good result to the inclusion of etoposide in a pretransplant regimen where, in addition, the dose of fractionated irradiation delivered was 1320 cGY. 20 Our study cannot compare such different approaches. It only highlights the possibility to decide early on the chances for cure with a transplant.
